ReviewNutrition & metabolism2025
Multi-omics research on moyamoya disease: current perspectives and future directions.
Review in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) is a rare, progressive cerebrovascular disorder characterized by internal carotid artery stenosis and compensatory vascular network formation. While its pathogenesis remains unclear, multi-omics approaches provide crucial molecular insights. Genomic studies identify significant associations with the RNF213 p.R4810K variant and other susceptibility loci like HLA-DQA2 and GUCY1A3. Transcriptomics reveals dysregulation in extracellular matrix organization and mitochondrial oxidative phosphorylation, with specific markers such as AQP4 and non-coding RNAs (e.g., miR-107). Proteomic analyses highlight alterations in proteins including VEGF, apolipoproteins (APOC1, APOD), and ferroptosis-related pathways. Metabolomics identifies diagnostic amino acid markers (L-lysine, L-glutamate) and altered lysophosphatidylcholine (LPC 16:1) levels. Epigenomics implicates DNA methylation changes in genes like SOX6 and KCNMA1. Integrated multi-omics facilitates the development of multifaceted treatments, including revascularization surgery, targeted molecular therapies, and personalized interventions based on individual omics profiles, advancing precision medicine for MMD. This article outlines the omics techniques' application progress in MMD, discussing their pros and cons in disease analysis, prevention, and treatment, aiming to guide future research and inform clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.